Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SCD | O00767 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23355345 | 0.89 | MAPT (0.44) | SIRT6MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL23355304 | 0.89 | SIRT6 (0.41) | SIRT6MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL23355348 | 0.88 | PDE4B (0.43) | SIRT6MAPTALDH1A1LMNA | |
| SCHEMBL30203345 | 0.88 | PDE4B (0.43) | SIRT6MAPTALDH1A1LMNA | |
| SCHEMBL23355428 | 0.85 | CTSV (0.42) | SIRT6MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL23355326 | 0.83 | SIRT6 (0.42) | SIRT6MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL21616255 | 0.82 | PDE5A (0.37) | SIRT6MAPTALDH1A1LMNAPDE5A | |
| SCHEMBL21612833 | 0.78 | PDE4D (0.47) | MAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL26113891 | 0.77 | SIRT6 (0.39) | SIRT6MAPTALDH1A1KDM4ELMNA | |
| SCHEMBL21612772 | 0.77 | PDE4B (0.44) | SIRT6MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
| WO-2020009156-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | 第一三共株式会社 | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230025510-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES | ERBB2, EGFR, ERBB3 | SIRT6 3508/4885MAPT 4074/4885ALDH1A1 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.